Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes
Authors' conclusion
Mini-dose glucagon with or without 50% reduction in CSII basal delivery rate may help to decrease EAH incidence in adults with type 1 diabetes.
Study context
- Population
- Adults with T1D on continuous subcutaneous insulin infusion (CSII) undertaking usual aerobic exercise at moderate to high intensity for 30 to 75 min in real-world settings48 completed training phase
- Participants
- 45 adults
- Comparison
- Mini-dose glucagon 150 µg vs placebo before exercise
- Primary endpoint
- Incidence of level 1 hypoglycemia based on SMBG (exercise-associated hypoglycemia)
- Follow-up
- 12-week outpatient phase
Methodological detailscrossover in-clinic training phase, rerandomised 12-week outpatient phase, open-label arm C
- Crossover in-clinic training phase
- Rerandomised 12-week outpatient phase
- Open-label arm C
Primary result
As reported in the abstract
Level 1 hypoglycemia, all exercise sessions (n = 795)
A vs B: P < 0.0001 · C vs B: P = 0.0032
Further findings
| Outcome | P value |
|---|---|
| Consumed grams of exercise carbohydratesGlucagon vs Placebo · lower with glucagon, not statistically significant | P = 0.12 |
Times below, in and above range, 0 to 300 min
- Did not significantly differ among treatment arms
Safety
- Adverse events were similar among treatment arms
Original publication
Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care. Published 23 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →